Table 2. Pathological response.
| Cohort 1: Capecitabine | Cohort 2: 5-FU | |||||
|---|---|---|---|---|---|---|
| PPI (51) | Non-PPI (200) | p value | PPI (52) | Non-PPI (144) | p value | |
| ypCR | 29.4% | 19.5% | 0.13 | 25.0% | 26.4% | 1.00 |
| ypPR | 47.1% | 52.5% | 61.5% | 50.0% | ||
| ypCR + ypPR | 76.5% | 72.0% | 0.60 | 86.5% | 76.4% | 0.16 |
| ypSD | 17.6% | 18.5% | 7.7% | 13.2% | ||
| ypPD | 8.8% | 9.5% | 5.8% | 10.4% | ||
PPI: proton-pump inhibitors; ypCR: pathological complete response; ypPR: pathological partial response; ypSD: pathological stable disease; ypPD: pathological progressive disease